Blockade of HLA Antibody-Triggered Classical Complement Activation in Sera from Subjects Dosed with the Anti-C1s Monoclonal Antibody TNT009 - Results from a Randomized First-in-Human Phase 1 Trial

• Published in: Transplantation
• Main Authors: Mühlbacher, Jakob, Jilma, Bernd, Wahrmann, Markus, Bartko, Johann, Eskandary, Farsad, Schörgenhofer, Christian, Schwameis, Michael, Parry, Graham C, Gilbert, James C, Panicker, Sandip, Böhmig, Georg A
• Format: Journal Article
• Language: English
• Published: United States 01.10.2017

Complement may play a key role in antibody-mediated rejection (ABMR). A promising therapeutic approach may be classical pathway (CP) inhibition at the level of early component C1. In this first-in-human, double-blind, randomized placebo-controlled phase 1 trial, we evaluated the safety and complemen...